MedTrace Logo

Comparative Study of Strategies for Management of Duchenne Myopathy (DM)

NCT03633565 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2018-08-16

No results posted yet for this study

Summary

1. Comparing different lines of treatment of Duchenne Myopathy (DM) and assessment of new lines of treatment (mesenchymal stem cell, phosphodiesterase inhibitors) in reducing the impact of disability in the patients with Duchenne Myopathy and slowing the progression of cardiomyopathy
2. Upsetting and implementation of the best treatment plan for those children with Duchenne myopathy which is suitable for the available resources in Assiut University Children Hospital

Conditions

  • Myopathy

Interventions

DRUG

Sildenafil (Phosphodiesterase inhibitors)

tablet 25mg

DRUG

Prednisolone (Steroids)

tablet 20 mg

PROCEDURE

Mesenchymal stem cell transplantation

stem cell transplantation intramuscular

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Emad EL Daly, Professor · Assiut University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
15 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-30
Primary Completion
2021-09-30
Completion
2021-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03633565 on ClinicalTrials.gov